Genetic engineers at Crop Genetics and Mycogen place hopes on two different strategies for pest control Like Babe Ruth, John Henry sees himself as a slugger. The president and CEO of Crop Genetics International of Hanover, Md., Henry is going for a grand slam in his field of pest control: a genetically designed biopesticide against the European corn borer, a pest that munches $500 million worth of corn annually in the United States. In contrast to his heavy-hitting strategy are the efforts of
Genetic engineers at Crop Genetics and Mycogen place hopes on two different strategies for pest control |
John Henry may owe his interest in modernizing agriculture to, well, his genes. A distant ancestor, Cyrus McCormick, invented the reaping machine in 1831, and parlayed that into what is now International Harvester Corp. Henry wants to help usher in the next revolution in agriculture - designing a plant vaccine for the world's grain crops ...
Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.
View this Issue
Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.
Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.
In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.
Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.
Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.
Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.
Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.
